G
Gerrit J.A. Vos
Publications - 11
Citations - 440
Gerrit J.A. Vos is an academic researcher. The author has contributed to research in topics: Acute coronary syndrome & Clopidogrel. The author has an hindex of 3, co-authored 10 publications receiving 231 citations.
Papers
More filters
Journal ArticleDOI
A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI
Daniel M.F. Claassens,Gerrit J.A. Vos,Thomas O. Bergmeijer,Renicus S Hermanides,Arnoud W J van 't Hof,Pim van der Harst,Emanuele Barbato,Carmine Morisco,Richard M. Tjon Joe Gin,Folkert W. Asselbergs,Folkert W. Asselbergs,Arend Mosterd,Jean-Paul R. Herrman,Willem Dewilde,Paul W.A. Janssen,Johannes C. Kelder,Maarten J. Postma,Anthonius de Boer,C. Boersma,Vera H.M. Deneer,Jurrien M Ten Berg +20 more
TL;DR: In patients undergoing primary PCI, a CYP2C19 genotype-guided strategy for selection of oral P2Y12 inhibitor therapy was noninferior to standard treatment with ticagrelor or prasugrel at 12 months with respect to thrombotic events and resulted in a lower incidence of bleeding.
Journal ArticleDOI
Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy.
Thomas O. Bergmeijer,Gerrit J.A. Vos,Daniel M.F. Claassens,Paul Wa Janssen,Remko Harms,Richard van der Heide,Folkert W. Asselbergs,Jurriën M. ten Berg,Vera H.M. Deneer +8 more
TL;DR: CYP2C19 genotyping is feasible in everyday clinical practice, both in the acute and non-acute settings, and may reduce atherothrombotic and bleeding events.
Journal ArticleDOI
Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype: A POPular Genetics Subanalysis.
Daniel M.F. Claassens,Thomas O. Bergmeijer,Gerrit J.A. Vos,Renicus S Hermanides,Arnoud W J van 't Hof,Pim van der Harst,Pim van der Harst,Emanuele Barbato,Carmine Morisco,Richard M. Tjon Joe Gin,Folkert W. Asselbergs,Folkert W. Asselbergs,Arend Mosterd,Jean-Paul R. Herrman,Willem Dewilde,Paul W.A. Janssen,Johannes C. Kelder,Bakhtawar K. Mahmoodi,Vera H.M. Deneer,Jurriën M. ten Berg +19 more
TL;DR: In this article, a prespecified subanalysis of the POPULAR Genetics trial was performed, using patients in whom CYP2C19*2, *3, and *17 genotypes was determined.
Journal ArticleDOI
Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial.
Daniel M.F. Claassens,Pim W. M. van Dorst,Gerrit J.A. Vos,Thomas O. Bergmeijer,Renicus S Hermanides,Arnoud W J van 't Hof,Pim van der Harst,Pim van der Harst,Emanuele Barbato,Carmine Morisco,Richard M. Tjon Joe Gin,Folkert W. Asselbergs,Folkert W. Asselbergs,Arend Mosterd,Jean-Paul R. Herrman,Willem Dewilde,Maarten J. Postma,Maarten J. Postma,Vera H.M. Deneer,Jurriën M. ten Berg,C. Boersma,C. Boersma +21 more
TL;DR: In this article, the authors evaluated the cost effectiveness of a genotype-guided P2Y12 inhibitor strategy compared with standard treatment with ticagrelor or prasugrel without increasing thrombotic event rates after primary percutaneous coronary intervention (PCI).
Journal ArticleDOI
Reasons for early discontinuing or switching of antiplatelet therapy in elderly patients after acute coronary syndrome.
TL;DR: Main reasons for discontinuing antiplatelet therapy are need for (N)OAC, undergoing CABG or type II ACS as final diagnosis and suffering from dyspnoea while on ticagrelor.